InsiderTrades.com logo

SLS Insider Trading

Insider Ownership Percentage: 1.40%
Insider Buying (Last 12 Months): $48,600.00
Insider Selling (Last 12 Months): $0.00

Galena Biopharma Insider Trading History Chart

This chart shows the insider buying and selling history at Galena Biopharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Galena Biopharma Share Price & Price History

Current Price: $1.57
Price Change: ▲ Price Increase of +0.01 (0.64%)
As of 06/18/2025 05:00 PM ET

This chart shows the closing price history over time for SLS up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Galena Biopharma Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/12/2025Nostrand Robert L VanDirectorBuy10,000$1.48$14,800.0020,400View SEC Filing Icon  
5/30/2025Jane WasmanDirectorBuy20,000$1.69$33,800.0030,400View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Galena Biopharma (NASDAQ:SLS)

17.38% of Galena Biopharma stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at SLS by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Galena Biopharma Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/14/2025Anson Funds Management LP7,579,095$8.19M1.3%+535.7%7.596%Search for SEC Filing on Google Icon
5/12/2025Virtu Financial LLC53,861$58K0.0%+30.9%0.057%Search for SEC Filing on Google Icon
2/28/2025Brooklyn FI LLC594,919$0.68M0.1%N/A0.845%Search for SEC Filing on Google Icon
2/17/2025Anson Funds Management LP1,192,266$1.24M0.1%+50.2%1.694%Search for SEC Filing on Google Icon
2/14/2025Northern Trust Corp134,721$0.14M0.0%+33.6%0.191%Search for SEC Filing on Google Icon
2/13/2025XTX Topco Ltd53,426$56K0.0%-14.9%0.076%Search for SEC Filing on Google Icon
2/12/2025Geode Capital Management LLC733,546$0.76M0.0%+21.2%1.042%Search for SEC Filing on Google Icon
2/11/2025Virtu Financial LLC41,155$43K0.0%-48.1%0.058%Search for SEC Filing on Google Icon
2/11/2025Brooklyn FI LLC594,919$0.68M0.0%N/A0.845%Search for SEC Filing on Google Icon
1/31/2025Opus Capital Group LLC238,500$0.25M0.0%+5.5%0.339%Search for SEC Filing on Google Icon
11/20/2024Virtu Financial LLC79,241$99K0.0%+24.1%0.113%Search for SEC Filing on Google Icon
11/16/2024Geode Capital Management LLC605,191$0.76M0.0%+17.1%0.941%Search for SEC Filing on Google Icon
11/15/2024Anson Funds Management LP793,835$0.99M0.0%N/A1.234%Search for SEC Filing on Google Icon
11/15/2024XTX Topco Ltd62,785$78K0.0%N/A0.098%Search for SEC Filing on Google Icon
11/15/2024State Street Corp174,529$0.22M0.0%+30.2%0.271%Search for SEC Filing on Google Icon
8/9/2024Renaissance Technologies LLC32,446$39K0.0%N/A0.056%Search for SEC Filing on Google Icon
5/20/2024Virtu Financial LLC39,429$40K0.0%-34.2%0.068%Search for SEC Filing on Google Icon
5/14/2024Anson Funds Management LP4,832,368$4.88M0.3%N/A8.366%Search for SEC Filing on Google Icon
4/26/2024Opus Capital Group LLC200,600$0.20M0.0%+48.6%0.356%Search for SEC Filing on Google Icon
2/13/2024Armistice Capital LLC820,000$0.87M0.0%N/A2.558%Search for SEC Filing on Google Icon
1/31/2024Opus Capital Group LLC135,000$0.14M0.0%+291.3%0.421%Search for SEC Filing on Google Icon
9/12/2023Prosperity Financial Group Inc.29,800$47K0.0%N/A0.105%Search for SEC Filing on Google Icon
5/11/2023Highbridge Capital Management LLC1,805,054$2.58M0.0%N/A6.367%Search for SEC Filing on Google Icon
1/18/2023Opus Capital Group LLC19,672$46K0.0%N/A0.096%Search for SEC Filing on Google Icon
11/15/2022Empery Asset Management LP308,466$0.62M3.7%-66.8%1.501%Search for SEC Filing on Google Icon
2/14/2022GSA Capital Partners LLP10,447$58K0.0%N/A0.066%Search for SEC Filing on Google Icon
2/11/2022Equitable Holdings Inc.102,000$0.56M0.0%+2.0%0.642%Search for SEC Filing on Google Icon
11/12/2021Jump Financial LLC14,627$0.13M0.0%N/A0.092%Search for SEC Filing on Google Icon
11/12/2021Equitable Holdings Inc.100,000$0.92M0.0%+6.0%0.630%Search for SEC Filing on Google Icon
11/12/2021Geode Capital Management LLC133,801$1.23M0.0%+32.0%0.843%Search for SEC Filing on Google Icon
8/25/2021Marshall Wace LLP84,544$0.94M0.0%+63.0%0.533%Search for SEC Filing on Google Icon
8/17/2021Price T Rowe Associates Inc. MD15,500$0.17M0.0%-42.8%0.103%Search for SEC Filing on Google Icon
8/16/2021Morgan Stanley15,499$0.17M0.0%+297.4%0.103%Search for SEC Filing on Google Icon
8/16/2021Pinz Capital Management LP10,700$0.12M0.0%-18.3%0.071%Search for SEC Filing on Google Icon
8/16/2021State Street Corp37,468$0.42M0.0%N/A0.248%Search for SEC Filing on Google Icon
8/16/2021Marshall Wace LLP84,544$0.94M0.0%+63.0%0.560%Search for SEC Filing on Google Icon
8/13/2021Northern Trust Corp24,605$0.27M0.0%+35.9%0.163%Search for SEC Filing on Google Icon
8/13/2021Geode Capital Management LLC101,337$1.12M0.0%+6.8%0.672%Search for SEC Filing on Google Icon
8/13/2021Vanguard Group Inc.618,534$6.87M0.0%+31.6%4.100%Search for SEC Filing on Google Icon
8/12/2021Dimensional Fund Advisors LP20,320$0.23M0.0%+31.9%0.135%Search for SEC Filing on Google Icon
8/12/2021Bank of Montreal Can109,282$1.43M0.0%N/A0.724%Search for SEC Filing on Google Icon
8/11/2021Bank of New York Mellon Corp20,332$0.23M0.0%+30.3%0.135%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Galena Biopharma logo
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Read More on Galena Biopharma

Today's Range

Now: $1.57
Low: $1.51
High: $1.57

50 Day Range

MA: $1.55
Low: $1.11
High: $1.94

52 Week Range

Now: $1.57
Low: $0.77
High: $2.12

Volume

2,541,799 shs

Average Volume

1,575,516 shs

Market Capitalization

$156.65 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.25

Who are the company insiders with the largest holdings of Galena Biopharma?

Galena Biopharma's top insider investors include:
  1. Jane Wasman (Director)
  2. Nostrand Robert L Van (Director)
Learn More about top insider investors at Galena Biopharma.

Who are the major institutional investors of Galena Biopharma?

Galena Biopharma's top institutional investors include:
  1. Anson Funds Management LP — 7.60%
  2. Virtu Financial LLC — 0.06%
Learn More about top institutional investors of Galena Biopharma stock.

Which institutional investors are buying Galena Biopharma stock?

In the previous quarter, SLS stock was purchased by institutional investors including:
  1. Anson Funds Management LP
  2. Virtu Financial LLC
During the last year, these company insiders have bought Galena Biopharma stock:
  1. Jane Wasman (Director)
  2. Nostrand Robert L Van (Director)
Learn More investors buying Galena Biopharma stock.